— As reported in an oral presentation, findings demonstrated selective activity of LYC-30937 against chronically activated, disease-causing immune cells while sparing normal cells in preclinical disease models and assays   — In a separate poster presentation a highly selective inhibitor of Rho kinase 2 showed broad anti-fibrotic activity in in preclinical assays NEW YORK and… Read More

NEW YORK and ANN ARBOR, Mich., Jan. 11, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that it entered into a license agreement with its collaboration partner Celgene Corporation.  Under the agreement, Lycera granted to Celgene an exclusive license for Lycera’s portfolio of novel ex vivoRORgamma agonist… Read More

NEW YORK and ANN ARBOR, Mich., Nov. 3, 2015 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that research findings from the Company’s RORgamma agonist program will be presented at this week’s annual meeting of the Society for Immunotherapy of Cancer, taking place in National Harbor, MD, November… Read More

NEW YORK and ANN ARBOR, Mich., Oct. 6, 2015 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the appointment of Alex G. Howarth as Chief Financial Officer. With over 25 years of experience in healthcare and financial advisory roles, Mr. Howarth brings to Lycera a distinguished track record… Read More

Transformational collaboration will focus on the advancement of Lycera’s innovative pipeline, including Lycera’s first-in-class RORgamma agonists for cancer immunotherapy, and clinical-stage candidate, LYC-30937, being studied for inflammatory bowel disease (IBD) NEW YORK and ANN ARBOR, Mich., June 9, 2015 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines announced today the… Read More

NEW YORK and ANN ARBOR, Mich., April 30, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough immunomodulatory medicines to treat autoimmune diseases and cancer, today announced the initiation of a Phase 1 clinical trial of LYC-30937 in healthy volunteers.  LYC-30937 is an oral gut-directed ATPase modulator that is being studied for the treatment… Read More

NEW YORK and ANN ARBOR, Mich., April 7, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that the Company will present preclinical research from its novel cancer immunotherapy program at the American Association of Immunologists (AAI) Annual Meeting, which will take place in New… Read More

NEW YORK and ANN ARBOR, Mich., Mar. 25, 2015 — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company’s collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment. The program, announced in… Read More

NEW YORK and ANN ARBOR, Mich., March 18, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that the Company will present preclinical research from its novel cancer immunotherapy program at the American Association for Cancer Research (AACR) Annual Meeting, which will take place in… Read More